Edwards Lifesciences Corporation (NYSE:EW) Short Interest Update

Key Points

• Edwards Lifesciences experienced a significant 29.9% drop in short interest in September, with current short interest totaling 7,260,000 shares.
• Research analysts have upgraded their price targets for Edwards Lifesciences, with a consensus price target of $86.61 and several analysts rating the stock as a "Strong Buy."
• Insider transactions include a sale by VP Daniel J. Lippis of 4,114 shares at an average price of $79.46, representing a 15.75% decrease in ownership.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totaling 7,260,000 shares, a drop of 29.9% from the August 31st total of 10,350,000 shares. Based on an average daily volume of 4,350,000 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.3% of the company's stock are sold short. Currently, 1.3% of the company's stock are sold short. Based on an average daily volume of 4,350,000 shares, the days-to-cover ratio is currently 1.7 days.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Mizuho increased their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Truist Financial upped their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Robert W. Baird raised their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price for the company in a report on Tuesday, July 29th. Finally, William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus price target of $86.61.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company's stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in EW. Rosenberg Matthew Hamilton acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $28,000. Quantbot Technologies LP bought a new stake in Edwards Lifesciences in the first quarter valued at about $26,000. NewSquare Capital LLC raised its position in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company's stock worth $29,000 after purchasing an additional 134 shares in the last quarter. SouthState Corp bought a new position in Edwards Lifesciences during the first quarter worth about $27,000. Finally, Rakuten Securities Inc. boosted its holdings in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.5%

EW opened at $77.03 on Monday. The business has a 50 day moving average of $78.50 and a 200-day moving average of $76.01. The stock has a market capitalization of $45.22 billion, a price-to-earnings ratio of 11.08, a P/E/G ratio of 3.71 and a beta of 1.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1-year low of $64.00 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm earned $0.70 EPS. The business's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.